A disease-associated gene desert orchestrates macrophage inflammatory responses via ETS2

Increasing global rates of autoimmune and inflammatory disease present a burgeoning threat to human health[1][1]. This is compounded by the limited efficacy of available treatments[1][1] and high failure rates during drug development[2][2] – underscoring an urgent need to better understand disease mechanisms. Here we show how genetics could address this challenge. By investigating an intergenic haplotype on chr21q22, independently linked to inflammatory bowel disease (IBD), ankylosing spondylitis, primary sclerosing cholangitis and Takayasu’s arteritis[3][3]–[6][4], we discover that the causal gene, ETS2 , is a master regulator of inflammatory responses in human macrophages and delineate how the risk haplotype increases ETS2 expression. Genes regulated by ETS2 were prominently expressed in affected tissues from chr21q22-associated diseases and more enriched for IBD GWAS hits than almost all previously described pathways. Overexpressing ETS2 in resting macrophages produced an activated effector state that phenocopied intestinal macrophages from IBD[7][5], with upregulation of multiple drug targets including TNFα and IL-23. Using a database of cellular signatures[8][6], we identify drugs that could modulate this pathway and validate the potent anti-inflammatory activity of one class of small molecules in vitro and ex vivo . Together, this highlights the potential for common genetic associations to improve both the understanding and treatment of human disease. ### Competing Interest Statement C.T.S., C.B. and J.C.L. are co-inventors on a patent application relating to this work. C.W. holds a part time position at GSK. GSK had no role in this study. [1]: #ref-1 [2]: #ref-2 [3]: #ref-3 [4]: #ref-6 [5]: #ref-7 [6]: #ref-8